Arch Biopartners Inc
Arch Biopartners Inc., based in Toronto, is a late-stage clinical company focused on developing innovative treatments for acute kidney injury (AKI). With its lead drug candidates, LSALT peptide and Cilastatin, the company aims to significantly improve outcomes for patients at risk of this debilitating condition, which affects millions annually in the US and Europe.
Dedicated to addressing organ inflammation, Arch Biopartners is advancing a therapeutic platform that targets key pathways involved in inflammation, including the DPEP1 enzyme. The company collaborates closely with the scientific community and research institutions to enhance the value of its therapeutic innovations and intellectual property for its investors.
Generated from the website

